OUTLOOK THERAPEUTICS INC
OTLKNASDAQTrading Snapshot
- Day Range
- $0.52 – $0.55
- 52-Week Range
- $0.16 – $2.54
- Volume (shares)
- 1,982,243
- Avg Volume (shares)
- —
- Shares Outstanding
- 243.4M
- Next Earnings
- 2026-12-17
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $9,000
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.87
- Dividend Yield
- —
- Dilution (1yr)
- +148.4%
OUTLOOK THERAPEUTICS INC
OTLK
StockOtter · stockotter.spaceAbout OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Xenetic Biosciences (NASDAQ:XBIO) versus Oncobiologics (NASDAQ:OTLK) Critical Analysis
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses ba
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA® and EYLEA® HD, to lead U.S. commercialization of LYTENAVA™ (bevacizumab-vikg) Veteran retina commercial leader, who has helped launch BEOVU®, EYLEA®
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion
Segment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company's path forward following the FDA approval of LYTENAVA™
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeuti
Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Ionis Pharmaceuticals, Inc. today announced positive topline results fro
Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK)
Synlogic (NASDAQ: SYBX - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the